Congratulations to Parkwalk portfolio companies Brainomix, Phoremost, and Congenica who have all been named as finalists at the annual OBN Awards.
‘The 11th Annual OBN Awards remains the life sciences industry’s most highly regarded awards event. Entry rates increased once again this year, with the quality of entries and levels of innovation consistently impressive across all categories.’
Congenica, revolutionising the way genetic diseases are characterised and diagnosed was also nominated for ‘Best Established Medtech Company’.
Brainomix, using AI and deep learning algorithms to develop a complete stroke imaging decision support solution to hospitals worldwide, was nominated for ‘Best Established Medtech Company’.
PhoreMost, applying a range of proprietary drug discovery platforms to develop a pipeline of novel therapeutics in oncology and other diseases, was nominated for ‘Best Emerging Biotech Company’.
The nominations highlight our investment strategy of backing best in class companies across a wide range of sectors. Fingers crossed for the final!
More information can be found here – https://obn-awards.com/
